Page 919«..1020..918919920921..930940..»

Meet the Researcher: Xiaomei Cong, School of Nursing – UConn Today

Posted: August 26, 2020 at 5:55 am

Babies who are born prematurely have to fight through days, weeks, or even months of stressful existence.

University of Connecticut School of Nursing professor Xiaomei Cong saw this struggle firsthand working as a registered nurse in a neonatal intensive care unit (NICU) early in her career. She watched as these vulnerable newborns underwent up to 20 painful procedures a day. She had always been a practitioner, but these experiences pointed her towards providing support through research and innovation.

These stressful events can have long-term neurobehavioral effects. These effects are one of the focuses of Congs research.

One of Congs earlier studies focused on how Kangaroo Care a method of holding newborns can alleviate NICU procedural pain. Kangaroo Care involves skin-to-skin contact, an important aspect for any babys development. Cong found for neonates undergoing painful procedures, this has an added benefit of alleviating some of the pain and stress that those procedures induce.

Cong also studies longer-term effects of these stressful events early in life. Focusing on children from birth to three years old, Cong looks at their language development, weight, height, emotional development, cognition and how these children respond to stressful events.

Much of Congs current research focuses on using biomarkers to measure stress in babies. Neonates cannot express when they are experiencing stress or pain in the same way older children can. Cong has thus looked to biomarkers like cortisol, a stress hormone and oxytocin, a love hormone or cuddle chemical in neonates saliva. These chemicals can tell researchers and clinicians a lot about how a baby is handling stress without words.

Whats in the gut

Congs research has recently pivoted to look at neonates microbiome. The microbiome is a dynamic system of bacteria, microbes, and other organisms that live in and on the human body. The organisms in the microbiome outnumber cells in a human body by approximately 10 to one.

The microbiome supports important digestion, immunity, and nutrition functions. A person accumulates their unique microbiome over their lifetime. Babies are born as a clean slate and begin growing their biome right from birth. The first few months of life are key to developing a healthy biome for the rest of a persons life.

They undergo big changes in those first few weeks of life, Cong says.

When babies are in the NICU, they are not exposed to the normal bacteria and microbes because their health is so fragile.

One of Congs current studies looks at mothers who are unable to breastfeed their infants in the NICU. Often, these babies will be tube-fed pasteurized breastmilk from donors. Compared to mothers own milk, this milk may have disadvantages, because pasteurization kills many of the helpful bacteria and microbes along with those which may endanger the babies nascent immune systems.

It has the same nutritional value, but hampers the development of the microbiome, Cong says.

Cong has found that milk from the babys own mother, even if it has to be through tube-feeding for the very premature infant, is better for the babys microbiome development than that of pasteurized donor milk.

This finding helps inform clinical practice, as doctors and nurses can encourage mothers to send their own milk to the NICU even when they cannot breastfeed directly.

Cong also studies stool samples from neonates to look for additional biomarkers that reveal the development and health of their microbiome, as well as the microbiome of people with Irritable Bowel Syndrome (IBS). Cong is studying the manifestations of emotional stress in patients with IBS using many of the same concepts she uses to study neonates in the NICU.

Keeping up with tech

More recently, Cong has also used genetic markers to study this aspect of neonates experience in the NICU. The emergence of genomic science has provided a new avenue for Cong to expand her research.

We always have these new technologies, Cong says. Especially in recent years with genetics and genome science, we really have to catch up with whats going on there.

These advancements have shown Cong how important fruitful collaborations with other researchers can be. Cong works with researchers at Connecticut Childrens Medical Center and The Jackson Laboratory for Genomic Medicine, who have expertise in areas that can inform her research.

You always have to learn some new thing, Cong says. And that often means you have to build up your team and work together.

Cong also works closely with the Microbial Analysis, Resources and Services (MARS) center, which is part of UConns Center for Open Research Resources and Equipment (COR2E), which conducts microbiome sequencing. Cong is also the director of the UConn School of Nursings Biobehavioral Research Lab.

All the collaborations are so important to our studies, Cong says. We get amazing results.

Not just on paper

One of the most rewarding aspects of her work for Cong is how directly it can be applied and have real-life impacts.

It goes into clinical practice, Cong says. Its not just on the paper.

The goal of Congs research is to improve the short- and long-term neurodevelopment and quality of life for babies who start their lives in the NICU.

Cong says she sees her research continuing in new directions facilitated by technological developments which support new avenues for her work.

Definitely we want to see all these babies have an improved quality of life and better health later in life, Cong says.

Follow UConn Research on Twitter & LinkedIn.

Excerpt from:
Meet the Researcher: Xiaomei Cong, School of Nursing - UConn Today

Posted in Human Genetics | Comments Off on Meet the Researcher: Xiaomei Cong, School of Nursing – UConn Today

Active Aging Could Eliminate the Retirement Funding Gap With the Help of Epigenetics – BRINK

Posted: August 26, 2020 at 5:54 am

Active aging allows individuals to continue to stay involved in the workforce and stay engaged with their pension and savings programs.

Photo: Unsplash

Share this article

Some scientists believe that the firstperson to live to 200 years old has already been born. But counting years on the calendar alone puts the focus on quantity, potentially overlooking quality of life, especially if one cannot be active. Modern medicine and technology can save lives; unfortunately, not as much work has gone into preventing illness as into treating it.

The data shows that as life expectancy continues to increase, people are running out of money for essentials, let alone factoring in the costs of maintaining health and seeking care. The pension gap (between actual savings and income needs) in the U.K. in 2015 was already at $8 trillion, estimated to rise at 4% per annum to reach $33 trillion by 2050. If we look at the top eight global economies, these figures are $70 trillion and $400 trillion, respectively, meaning this is not an isolated problem. In the U.K., at an individual level, this equates to running out of money 10.3 years before you die if you are a man and 12.6 years before you die if you are a woman on average. Can you imagine the gap if we live to 200? For many employees, financial stress is already their number one worry, and 85% tell us that they trust their employers to prepare them adequately for retirement.

Working longer whether its because you have to or want to could close these financial gaps if you have the right information and means, but you need to be active to do so. The fastest-growing employment segment in many developed economies is the over-55s, which means a much larger percentage of older workers are now in employment than ever before. In the U.K., over-55s represented more than 50% of employment growth in the decade to 2018, a trend expected to continue in the next 10 years. Its clear, therefore, that we need to find ways to add healthy years to life, not just years.

Its also clear that what we have done in the past has not solved the problem. We need to enable long-term behavior change to ensure that people enjoy better health and stay active. And thats hard.

Many consider genetics to be the cards we are dealt. Our genes are fixed, and therefore, we are left with the bad and the good that come with them. This may well be true to an extent. However, we have something that sits above the genes known as the epigenome a network of chemical compounds surrounding DNA that have a role in determining which genes are active in a particular cell.

The study of these genetic interactions and changes is called epigenetics, which has become a field of urgent and intense research and may offer us a way of looking at how outcomes can be altered. By changing certain environmental factors such as physical activity, diet, stress and chronic pollution levels lets call these lifestyle interventions your genes may start to behave differently, leading to better quality, more energetic and non-sick aging. This active aging allows individuals to continue to participate in social, economic, cultural and civic activities, as well as remain physically active, stay involved in the workforce and stay engaged with their pension and savings programs. Active aging, therefore, could help minimize, or even eliminate, the funding gap. Additionally, healthy older adults are less at risk of severe consequences of COVID-19.

Muhdo Health has found that by testing individuals epigenetics and applying specific lifestyle interventions, we can expect to see an improvement in their quality of life. Workers get the opportunity to keep working for longer, reduce fatigue and, as a result, enjoy a happier retirement with less worry about the need for care in older (chronological) age.

Many types of workers may benefit from this approach. With the help of epigenetic monitoring, adjustments can be made to workflow, stress management and nutrition and the impact could be measured and controlled.

An employer in the building industry found that its older, more experienced workers were essential to the successful delivery of high-end projects. The continued health of this group of employees was so crucial that the employer implemented a Muhdo measure and monitor process to establish what the right working patterns and interventions should be. Once individuals had been tested and knew the steps they could take to improve their quality of life, they could set their own hyper-personalized goals and put change processes in motion.

Behavior change comes at different speeds not everyone can fix a lifetimes worth of bad habits overnight. But knowing how to add healthy years to your life by understanding your epigenetics may certainly help drive behavior change in a positive direction.

In addition to helping employees identify individual action plans, this employer found that it could help further by adjusting work and shift patterns to allow for more flexibility for this group of older, more experienced workers. Creating more flexibility reduced stress levels and improved engagement. This type of flexible work in later life is becoming increasingly prevalent. More than three-quarters (76%) of employees in Mercers 2020 Global Talent Trends Study said that they intended to continue working in some shape or form beyond the official retirement age, and 24% planned to work fewer hours. Up to 57% of employers already offer part-time work pre- and post-retirement as a means to embrace the value of older workers, and 46% are building a pool of retiree talent to tap into. These approaches could become even more useful for everyone by adding healthy active years to the mix.

And if a simple saliva test (repeated at intervals, say, quarterly or annually) could enable a future with less back pain, fewer muscle aches and injuries, less sickness, and even improved mental health as a result of better physical health then workers and employers rejoice!

We believe there are two key learnings to take forward:

Proactive epigenetic testing can enable employees to enjoy more healthy and active years. Epigenetic testing could be the way to unlock much-needed behavior change and the adoption of smarter lifestyle choices.

Flexible working arrangements can reduce stress, and improve productivity and financial resilience, closing the income gaps referred to earlier. They can be even more effective closer to retirement to allow for working in later life and retaining critical experience and skills.

Epigenetics research and the implications of lifestyle-related changes in the cause of disease and aging holds great promise. It could unlock our understanding of how an individual responds to environmental cues and acquired risk factors. It also raises profound ethical questions about the role of the employer and the efficacy of workplace programs and conditions and their unintended consequences.

Read the original here:
Active Aging Could Eliminate the Retirement Funding Gap With the Help of Epigenetics - BRINK

Posted in Epigenetics | Comments Off on Active Aging Could Eliminate the Retirement Funding Gap With the Help of Epigenetics – BRINK

Epigenetics Market Size and Growth 2020-2027 | Major Players Qiagen, Novartis AG, Active Motif, Merck Sharp & Dohme Corp, Thermo Fisher…

Posted: August 26, 2020 at 5:54 am

Fort Collins, Colorado Reports Globe recently published a report on the Epigenetics Market. The study was supported by data obtained either from primary sources or from corporate databases. The experts in the market have confirmed that the data is realistic and relevant to the particular market conditions and therefore will prove extremely helpful to the user. The factors that have been broken down into driver and restraint systems. The regions, types, applications, and strategies are segmented and subdivided for better and better understanding.

This report covers the current economic impact of COVID-19. This outbreak drastically changed the global economic situation. The current scenario of the constantly evolving corporate sector, as well as the present and future assessment of the impact, are also addressed in the report.

Epigenetics market garnered a revenue of USD 7.4 billion in the year 2019 globally and has been foreseen to yield USD 30.1 billion by the year 2027 at a compound annual growth (CAGR) of 18.9% over the forecast period.

The Epigenetics marketreport gives a 360 approach for a holistic understanding of the market scenario. It relies on authentically-sourced information and an industry-wide analysis to predict the future growth of the sector. The study gives a comprehensive assessment of the Epigenetics industry, along with market segmentation, product types, applications, and value chain.

Leading Epigenetics manufacturers/companies operating at both regional and global levels:

F. Hoffmann-La Roche Ltd

The report also inspects the financial standing of the leading companies, which includes gross profit, revenue generation, sales volume, sales revenue, manufacturing cost, individual growth rate, and other financial ratios.

Research Objective:

Our panel of trade analysts has taken immense efforts in doing this group action in order to produce relevant and reliable primary & secondary data regarding the Epigenetics market. Also, the report delivers inputs from the trade consultants that will help the key players in saving their time from the internal analysis. Readers of this report are going to be profited with the inferences delivered in the report. The report gives an in-depth and extensive analysis of the Epigenetics market.

The Epigenetics Market is Segmented:

Epigenetics Market, By Technology (2016-2027)

Epigenetics Market, By Application (2016-2027)

Epigenetics Market, By Product (2016-2027)

This Epigenetics report umbrellas vital elements such as market trends, share, size, and aspects that facilitate the growth of the companies operating in the market to help readers implement profitable strategies to boost the growth of their business. This report also analyses the expansion, market size, key segments, market share, application, key drivers, and restraints.

Epigenetics Market Regional Analysis:

Key Coverage of Report:

Key insights of the report:

How Reports Globe is different than other Market Research Providers

The inception of Reports Globe has been backed by providing clients with a holistic view of market conditions and future possibilities/opportunities to reap maximum profits out of their businesses and assist in decision making. Our team of in-house analysts and consultants works tirelessly to understand your needs and suggest the best possible solutions to fulfill your research requirements.

Our team at Reports Globe follows a rigorous process of data validation, which allows us to publish reports from publishers with minimum or no deviations. Reports Globe collects, segregates, and publishes more than 500 reports annually that cater to products and services across numerous domains.

Contact us:

Mr. Mark Willams

Account Manager

US: +1-970-672-0390

Email:[emailprotected]

Web:reportsglobe.com

View post:
Epigenetics Market Size and Growth 2020-2027 | Major Players Qiagen, Novartis AG, Active Motif, Merck Sharp & Dohme Corp, Thermo Fisher...

Posted in Epigenetics | Comments Off on Epigenetics Market Size and Growth 2020-2027 | Major Players Qiagen, Novartis AG, Active Motif, Merck Sharp & Dohme Corp, Thermo Fisher…

New healthtech partnership set to unlock the power of personalised bioelectrical treatment using DNA sequencing – PR Newswire UK

Posted: August 26, 2020 at 5:54 am

- Genomics analysts Muhdo and bioelectronics experts NuroKor to launch personalised health profile KorDNA

- With a simple saliva test, users can access personalised health and lifestyle advice that could unlock the human body's full potential

- By combining big data DNA analytics the platform is set to provide bespoke bioelectrical treatments to suit a user's own genomic sequencing

LONDON, Aug. 26, 2020 /PRNewswire/ -- In the first partnership of its kind, two healthtech startups NuroKor and Muhdo have announced a collaboration to bring together the science behind bioelectronics and DNA data sequencing to personalise the recovery processes that occur post-workout, injury, and illness.

Muhdo's DNA and epigenetic analysis allows for a personal understanding of your own recovery and inflammation and NuroKor's devices help you take control of it. Using scientifically-proven, personalised bioelectronic medicine, NuroKor can support pain management and injury rehabilitation, as well as improving recovery from exercise and training.

As healthcare moves towards individualised treatments, so too does wellness and training. Muhdo provides all the information needed to build a data-driven, customised approach to rehab, prehab and performance. This, supported by the NuroKor BioElectronic system, can allow consumers to track the impact of Electrical Muscular Stimulation (EMS), and assist them in boosting results, whilst tracking biomarkers that identify inflammation and epigenetic age.

KorDNA has been developed with a focus on personalisation. The non-invasive saliva test provides users with detailed insight into their own DNA profile and an understanding of how environment and lifestyle can affect genetic expression, as well as personalised health recommendations including tailored workout plans and nutrition, training, treatment and recovery guides. With this detailed and highly individualised information, users are supported to meet their own health needs and goals.

Commenting on how improved awareness of genetic factors could aid with injury and exercise recovery, Dr Leah Austin, GP and Nutritional Therapist said:

"The ability to build a bespoke management plan using a NuroKor device, which is based on an in-depth understanding of personal genetic disposition has the potential to profoundly improve recovery from training for people exercising at all levels. I know from my own personal and professional experience that some people's bodies take much longer to rest and repair from strenuous activity. I once cycled from Lands End to John O'Groats and experienced significant swelling, also known as oedematous - at the time I didn't have a recovery plan but if I'd had a routine that took into consideration my genetics using a simple and effective device like NuroKor, my experience could've been very different."

Through continued collaboration, the two startups are already exploring new ways to integrate bioelectronics into DNA profiling to assist with even more highly personalised treatment protocols foroptimal pain treatment or increased training performance and muscle development.

"Epigenetics is the science that explains how your genes behave. You are born with your genetic makeup, but how those genes are expressed is affected by lifestyle," explains the Chief Executive of Muhdo, Nathan Berkley. "Our partnership with NuroKor and the development of the KorDNA profile will allow users to monitor core areas of their health, diet and vitamin levels, psychology, and physical condition to provide a means to better understand their body and maximise its potential."

Building on this Rick Rowan, CEO and Founder of NuroKor BioElectronics comments: "By collaborating with Muhdo, we can better understand the epigenetic factors that impact individuals. Together, we will be able to provide personal, easy-to-understand DNA diagnostics and real-time user sensor analytics via the app - the combination of our bioelectronic treatment applications and Muhdo's data analytics has the potential to improves lives, whether your aim is to recover from injury or illness, or to simply get fitter."

KorDNA is available to buy starting at [99] at http://www.nurokor.co.uk

NOTES TO EDITORS

If you would like to interview Rick, Leah or Nathan contact:

somX

James Somauroojs@somx.com

Houston

Alexander ClellandFiona Callmuhdo@houston.co.uk 0203 701 7660

For imagery, please access available images via here.

About NuroKor

Founded in 2018, NuroKor is a business committed to the development of bioelectronic technologies. NuroKor develops and formulates programmable bioelectronic software forclinical and therapeuticapplications, in a range of easy to use, wearable devices. It provides the highest-quality, medically regulated products, delivering personalised pain relief and recovery support and rehabilitation to patients.

About Muhdo

Muhdo is the first company in the world to offer a true internal wellness epigenetic profiling programme direct to companies and consumers, inspiring and supporting people to live healthier, happier, longer lives. As a next generation genetic and big data company, its vision is the mass personalisation of preventive and curative health through epigenetics and analytics, delivering a truly holistic and objective health and wellness programme.

https://nurokor.com

SOURCE Nurokor; Muhdo

See the original post:
New healthtech partnership set to unlock the power of personalised bioelectrical treatment using DNA sequencing - PR Newswire UK

Posted in Epigenetics | Comments Off on New healthtech partnership set to unlock the power of personalised bioelectrical treatment using DNA sequencing – PR Newswire UK

Q&A: discussing cancer blood testing tech with Volition – Verdict Medical Devices – Medical Device Network

Posted: August 26, 2020 at 5:54 am

]]]]]] Volitions CEO, Cameron Reynolds spoke to Medical Technology about the companys story so far and what sets their technology apart from others in development. Credit: Volition

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.

Epigenetics company Volition is hoping to carve new ground in the cancer diagnostics space. Through measuring tumour nucleosomes (a type of epigenetic structure) in the blood, it is creating a range of blood tests that can detect cancer from the earliest stages. The company says these tests will be simple, cost-effective and easy to use.

With clinical trials underway, the company is now focused on bringing its toolbox of diagnostic products to market. Volitions CEO, Cameron Reynolds spoke to Medical Technology about the companys story so far and what sets their technology apart from others in development.

Abi Millar (AM): Whats the story behind Volition? Can you tell me a bit about your path to getting where you are today?

Cameron Reynolds (CR): We started ago nearly ten years ago, in September 2010. Were still using the same technology platform as we were then a lot of companies chop and change, but weve always believed in epigenetics and see them as really important in cancer diagnosis.

We started with one original patent application, which was licensed to us from Chroma Therapeutics. We wanted to commercialise this basic concept of using nucleosomes (a type of epigenetic structure) for a marker for cancer detection, and eventually a number of other diseases as well. So we set up a subsidiary in Belgium, which we felt was a good value place to develop research, and raised just over a million euros. We also have offices in Texas, London and Singapore.

Our whole ethos has been to make low-cost, routine cancer diagnostics with an ELISA based format. The ELISA platform is 35 years old our chief scientific officer Jake Micallef has been working on this format his entire life, and hes a big believer in keeping it affordable.

We started with our original patent, which was histone modifications, and then we patented everything else we did along the way, so we have very strong intellectual property. We began with diagnostics for human cancers, starting with colorectal, and then adding in lung cancer and some other cancers where weve had some good results.

Around two and a half years ago, we expanded the staff and moved into a bigger facility in Belgium. We now have 35 people working there, attempting to create a robust, reliable stable platform to measure the tumour nucleosomes in circulation. We went public in 2015 on the New York Stock Exchange, since the capital markets are quite a good source of funding if you have something new and innovative.

Since then weve just been swimming in our own lane, developing our technology. Were in the process of launching a range of products over the next few years, and hopefully we can really do a good job with it.

AM: You are developing a range of blood tests for cancer diagnostics called Nu.Q, which has been described as an epigenetic toolbox. What is Nu.Q exactly? How does it work?

CR: We have several different ways of analysing the nucleosomes, ranging from a very simple microtitre plate-based ELISA format to a magnetic bead-based ELISA format. The new process were developing now, called Nu.Q Capture, involves capturing the nucleosomes on the machine, isolating them from the plasma, and conducting mass spectrometry analysis. This enables a greater concentration of nucleosomes.

Were using Nu.Q for our own purposes in cancer trials and other trials, and have also partnered with Texas A&M Veterinary School to find out whether our basic format could be useful in veterinary science too. Thats why we call Nu.Q a complete toolbox. Its a very robust reliable platform that can be used in all these different areas, and its a whole new way of analysing the epigenetic structures.

AM: What is different about this method, compared to other diagnostic assays for cancer?

CR: Since we started, there have been a lot of different cancer diagnostics in development, based on circulating tumour cells, DNA, exosomes, etcetera. But were still the only group ever to have looked at nucleosomes in circulation as a diagnostic.

We also have the ethos to keep it very affordable and easy to use. With a lot of companies its a complicated, expensive technology circulating DNA for instance requires a very large blood draw and quite expensive processes. Weve kept it simple, and we can do that because the markers were after are common in the blood and you can measure them with a simple ELISA format.

So theres always space for lots of different methods, but we think theres a very strong need for a low cost, reproducible reliable test that can be taken by huge numbers of people around the world as part of their normal medical work. That makes us unique not only in terms of the markers were after the nucleosomes but also in terms of the basic ethos. Weve spent the last two and half years fully optimising the platform itself so it can be robust, reproducible and reliable and accessible to any lab in the world.

AM: You currently have a number of clinical trials underway and presented some initial data at the 2020 ASCO Annual Meeting. What might the path to the clinic look like?

CR: We now have some markers that have shown very good efficacy in a range of cancers, but were also looking for differential markers between the different cancers. Were running some smaller trials for lung, colorectal and blood cancers some of the data was released at ASCO and now were putting together panels of those to get enough accuracy for a frontline test.

We also have some larger trials, like the early detection research network in the US, which will involve around 7,000-8,000 people. There are also some in Taiwan for lung and colorectal cancers, which will involve around 8,000-9,000 altogether.

So, weve got small and medium-sized trials along with some very large product trials. Thats on top of the trials we have in the veterinary space, as well as trials for things like Nu.Q Capture. Weve also had some very encouraging data in Covid-19, where were looking at prognostic outcomes.

Our assays are very low cost and easy to run with small amounts of blood, so we can run them in lots of different areas. There should be a lot of results coming through this year, next year and into 2022.

AM: What are your hopes for the future? What could the implications of your technology be further down the line?

CR: My hope is that our kits will enable much earlier diagnosis. That would really help to lower costs both in human terms and financially. If you get diagnosed early, you can survive it a lot longer of those diagnosed in stage 1, about 95% survive five years or more whereas its exactly the opposite if the cancer is found in stage 4. Thats obviously horrible for yourself and your family but its also a financial burden for health systems.

So hopefully it will have a very strong human impact on limiting the severity of the disease, as well as saving health systems and individuals money. This will make it affordable for healthcare systems in the developed and developing world, so we can hopefully save lives worldwide. And what we hope is that in five years, a large percentage of the worlds population who are either of age or at risk take our blood tests through routine blood work and we can do a lot of good in a lot of different areas.

AM: More generally, what do you expect the future of blood testing for cancer to look like?

CR: I certainly hope the other tests succeed, because particularly in markets like the US where there is an appetite for expensive tests, I think they could be very useful and some of them could be very accurate. So thats always a good thing, but what were providing is a routine, easy to use, lower cost alternative.

I think there are going to be things happening at both ends of the market, both at our end and also at the more complicated end of the market. A lot of it will be based on the epigenetics and not just the DNA the complete package of the epigenetics, the nucleosomes and the whole chromosome will make a big difference.

So, there are quite a few things in development that may work and I think theres going to be a real revolution in cancer diagnostics over the next five years. People will be able to get blood tests to get diagnosed early and hopefully well be a part of that.

Read the rest here:
Q&A: discussing cancer blood testing tech with Volition - Verdict Medical Devices - Medical Device Network

Posted in Epigenetics | Comments Off on Q&A: discussing cancer blood testing tech with Volition – Verdict Medical Devices – Medical Device Network

As Claudia Schiffer turns 50, we reveal the skincare products she actually uses – Telegraph.co.uk

Posted: August 26, 2020 at 5:54 am

It seems like only yesterday that Claudia Schiffer and her supermodel colleagues Cindy, Linda, Naomi and Christy ruled the runwaysin the 1990's. But in reality, it's been a good few decades since the original 'supers' reigned supreme.

Still, it's those same faces that many of usGen X'ers continue toaspire to, especially as many of them are now in their 50's- and looking better than ever - without obvious cosmetic procedures or surgery.

Claudia Schiffer turns 50 today, yetshe could easily be mistaken for someonein her 30's. Of course she does, she's got ridiculouslygood genes, I hear you scoff. Ah,but it's not as simple as allthat.

While there is no doubt that Claudia won the facial lottery, there's plenty of 'traditionally' beautiful starlets whose lookshave crumbled under the accumulationof life's many stresses - and some typically ordinary faces who have grown more youthful looking with age.

The common denominator in looking good, it seems, is lifestyle -or to be fancy about it, epigenetics: the effects thatour external lifestyle choices have on our perceived age.

Claudia's attitude to ageing is a holistic one. She believes in taking care of herface with natural organic skincare, eating healthily, exercisingandbeing out in nature. Which would explain why she's teamed up with organic lifestyle brand,Bamford, to launch an exclusive limited editionbeauty bag to celebrate her 50th birthday - a chosen edit of theactual products that Schiffer has been using on her face and body for years.

I was dying to know what's inside her limited edition collectionso that I can slap it all on in a bid to reach 50 looking half as youthful as she does, and I suspect you're curious too.

The bespoke bag designed by Carole Bamfordand Claudia contains a selection of five daily skincare and wellness essentials that are inClaudias beauty regime tocelebrates'the confidence that comes with age when you look after your health and well-being.'

Claudiasays, 'Im thrilled that in celebration of my 50th birthday Bamford have curated the products I use in my daily routine,into a limited-edition set, complete with a bespoke Claudia beauty bag. I love natural skincare and have used Bamfords products for years. They contain no harmful chemicals or preservatives, feel luxurious and are effective. Their organic and sustainable ethos is also very important to me.'

See the original post here:
As Claudia Schiffer turns 50, we reveal the skincare products she actually uses - Telegraph.co.uk

Posted in Epigenetics | Comments Off on As Claudia Schiffer turns 50, we reveal the skincare products she actually uses – Telegraph.co.uk

Cambodias Rithy Panh Discusses the Ethical Quandaries of Irradiated at the Sarajevo Film Festival – Variety

Posted: August 26, 2020 at 5:54 am

Cambodian director Rithy Panh survived the brutal Khmer Rouge regime that took the lives of many of his friends and family. His latest film Irradiated, which premiered in competition at the Berlin International Film Festival, does not shy away from human horrors like those he experienced in his youth.

The film pieces together brutal black-and-white archival war footage spread across a tryptic of panels, juxtaposing footage of Hitler with the devastation of Hiroshima and a basket of decapitated heads, or executions and mass burials.

Irradiated is a difficult, visceral viewing experience an artistic choice that Panh pondered seriously, he said in a recent masterclass at the Sarajevo Film Festival moderated by Variety.

Of course theres a moral question. Why do you want to show this body? Its possible to show a body, or not to. Its a difficult [decision] in both the selection and editing process, Panh acknowledges. Why this [image] and not another one? And why at this place and not another place?

Panh reflected on the work of Claude Lanzmann, who chose not to use gruesome archival footage in his iconic documentary Shoah, and Alain Resnais, who did in Night and Fog, excerpts of which appear in Irradiated. In the end, he decided to make use of such imagery because it helped him delve deeper into his understanding of his own dark past, and the broader question of human evil.

I watched a lot of images and decided to use only those that had an echo on me, that I came to [having had] the same experience, he said.

The choice to use disturbing footage of Nazis tossing corpses from recently liberated concentration camps into a mass grave, for instance, was a difficult one. I did it myself in another context, says Panh, who was forced as a young man to bury bodies in the same fashion. Its a scene for me about why we dont respect [them] more, these bodies? If an image echoes or resonates in my mind, I assume the responsibility to edit it.

History, for Panh, thus becomes raw material for personal inquiry. He feels it justifiable to submit viewers to such a disturbing onslaught because his creative act of filmmaking is itself a defiance of such violence, and a step in the process of rebuilding himself.

Creativity is a fight against the destruction, he said.

When he started working on Irradiated, he spent nearly two years of work on the film in Japan speaking with the hibakusha the irradiated people, as Panh calls them who are the surviving victims of the atomic bombings of Hiroshima and Nagasaki.

An encounter with lab mice at an epigenetic research lab in Zurich, however, changed the entire direction of the film. Whereas normal mice will try to swim when placed in water, the descendants of traumatized mice will give up quickly, allowing themselves to drown and die, he cites. After discovering epigenetics, when I got back to the film it was a whole other thing, he said.

Cinema is important for me, says Panh. It reverts [traumatic] processes for me and teaches me how to swim. Irradiated is perhaps a way for me to understand, maybe, my own situation, and what I can do to not transmit this trauma.

When asked about a present atrocity, the ongoing incarceration and oppression of the Uighur people in Chinas northwestern region of Xinjiang, Panh, one of cinemas foremost chroniclers of genocide, did not have any comment specific to that situation.

He instead broadened his response to condemn the way digital media cuts us off from opportunities for the type of deep reflection needed to live harmoniously together and to create great cinema.

For me, its more than [just a matter of] country; the digital also censors us a lot, he said. When information moves too quickly, there is no time for reflection, leading people to be easily manipulated, he explained. Now people want immediate pictures, immediate info, [but] you need time to analyze, to watch, to step back. Its become a way to censor a diversity of points of view.

Panh, by contrast, is a fan of taking things slow.

He was supposed to start shooting a new film in March, but has grounded those plans for now while it remains impossible to travel due to COVID-19. The pandemic has given him time to stop and talk to his vegetables in the garden and notice the increase of birdsong in Paris. Hes mulling his next projects, which include a documentary on the symbolic use and commercial exchange of Cambodian statuary, and perhaps new ventures inspired by COVID on how animals come to take power in cities as they empty of human presence, or the rise of totalitarian governance tactics in response to the virus.

Cinema is on death row now, he added. Modern filmmaking is all about speed, he assesses, and the movie industry puts more money in digital platforming and less and less towards cinema as literature. One day we will all be dead from this kind of lack of reflection.

See the rest here:
Cambodias Rithy Panh Discusses the Ethical Quandaries of Irradiated at the Sarajevo Film Festival - Variety

Posted in Epigenetics | Comments Off on Cambodias Rithy Panh Discusses the Ethical Quandaries of Irradiated at the Sarajevo Film Festival – Variety

Epigenetics Market 2020-2026: Global economy,Financial Share, Prominent Players,Competitive Environment,Types and Applications of Product/Service…

Posted: August 26, 2020 at 5:54 am

CMI published a business research report on Epigenetics Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts 20202027. Epigenetics Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. The information is gathered based on modern floats and requests identified with the administrations and items.

Click To Get Free PDF Brochure: https://www.coherentmarketinsights.com/insight/request-pdf/1772

The worldwide Epigenetics Market report stresses the most recent advancements, development, new chances, and lethargic traps. It gives a comprehensive position of the worldwide Epigenetics Market. The Epigenetics Market research report covers the present scenario and the growth prospects of the global Epigenetics Market industry for 2020-2027. The report enlists several important factors, starting from the basics to advanced market intelligence which play a crucial part in strategizing. Epigenetics Market manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the Epigenetics Market industry.

Leading Market Player Profile Included in This Report is: Illumina Inc., Thermo Fisher Scientific Inc., Merck Millipore Limited, Bio-Rad Laboratories, Inc., Qiagen Inc., Zymo Research Corporation, Diagenode s. a., Enzo Life Sciences, Inc. and New England Biolabs Inc.

Most of the information assembled is exhibited in a graphical frame alongside the related measurements. The Epigenetics Market report exhibits the working of the fundamental market players, providers, and merchants in detail. The report likewise features the limitations and drivers affecting the Epigenetics Market.

The report likewise incorporates a fundamental profile and data of all the significant market players at present dynamic in the worldwide Epigenetics Market. The organizations canvassed in the report can be assessed based on their most recent advancements, monetary and business diagram, item portfolio, enter drifts in the market, long haul and here and now business methodologies by the organizations with the end goal to remain aggressive in the market.

Get Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/1772

Important Features of the Epigenetics Market:

To build up a far-reaching, verifiable, every year refreshed and financially savvy data dependent on execution, capacities, objectives, and systems of the worlds driving organizations.

To help current providers reasonably evaluate their money related, advertising and innovative capacities opposite driving contenders.

To help potential market contestants in assessing imminent acquisitions and joint endeavor hopefuls.

To supplement associations inner rival data gathering endeavors by giving vital investigation, information understanding, and knowledge.

To distinguish the slightest focused market specialties with huge development potential.

Global Epigenetics Market: Regional Segment Analysis

North America (U.S., Canada, Mexico),

Europe (Germany, U.K., France, Italy, Russia, Spain etc),

South America (Brazil, Argentina etc)

Middle East & Africa (Saudi Arabia, South Africa etc).

Asia-Pacific (China, Japan, India)

In order to get a deeper view of Market Size, competitive landscape is provided i.e. Revenue (Million USD) by Players (2015-2020), Revenue Market Share (%) by Players (2015-2020) and further a qualitative analysis is made towards market concentration rate, product/service differences, new entrants and the technological trends in future.

An Overview of the Impact of COVID-19 on this Market:

The pandemic of COVID-19 continues to expand and impact over 175 countries and territories. Although the outbreak appears to have slowed in China, COVID-19 has impacted globally. The pandemic could affect three main aspects of the global economy: production, supply chain, and firms and financial markets. National governments have announced largely uncoordinated, country-specific responses to the virus. As authorities encourage social distancing and consumers stay indoors, several businesses are hit. However, coherent, coordinated, and credible policy responses are expected to offer the best chance at limiting the economic fallout.

National governments and international bodies are focused on adopting collaborative efforts to encourage financial institutions to meet the financial needs of customers and members affected by the coronavirus. However, there are some sectors that have remained unscathed from the impact of the pandemic and there are some that are hit the hardest.

We, at Coherent Market Insights, understand the economic impact on various sectors and markets. Using our holistic market research methodology, we are focused on aiding your business sustain and grow during COVID-19 pandemics. With deep expertise across various industries-no matter how large or small- and with a team of highly experienced and dedicated analysts, Coherent Market Insights will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future.

We Offer Customized Report, Click @ https://www.coherentmarketinsights.com/insight/request-customization/1772

Available Customizations

As per specific needs customizations of the given market data is also available. Talk to our research consultant to design an exclusive report as per your research needs like Regional and country-level analysis of market by end-use, detailed analysis and profiles of additional market players.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. ShahCoherent Market Insights1001 4th Ave, #3200Seattle, WA 98154Phone: US +12067016702 / UK +4402081334027Email: [emailprotected]

Read more here:
Epigenetics Market 2020-2026: Global economy,Financial Share, Prominent Players,Competitive Environment,Types and Applications of Product/Service...

Posted in Epigenetics | Comments Off on Epigenetics Market 2020-2026: Global economy,Financial Share, Prominent Players,Competitive Environment,Types and Applications of Product/Service…

Diabetes: Can A Plant Based Diet Help Control Blood Sugar Levels? Nutritionist Shares The Pros And Cons Of This Diet – NDTV

Posted: August 25, 2020 at 4:54 am

Diabetes: Your diet play an important role in maintaining healthy blood sugar levels

Diabetes is a progressive condition and chronic condition which requires constant management of blood sugar levels. If diagnosed early, the progression can be slowed considerably with therapeutic diet and physical activity. But if left uncontrolled, the blood sugar levels may start affecting different organs of the body. It is advised that diabetics should keep a constant check on the blood sugar levels and follow all necessary precautions to avoid major fluctuations.

Physical activity helps in controlling progression of the condition. But what is not clear is the ideal dietary pattern to be followed. There is a lot of uncertainty in nutrition claims, what was true yesterday may have some other aspects to reconsider with emerging research studies. One such research is about how effective is a plant-based diet in managing diabetes. In this article, Mrs. Sweedal Trinidade who is anutritionist and senior dietetics officer at P.D. Hinduja National Hospital explains in detail the pros and cons of a plant-based diet and its effect on diabetes.

A plant-based diet focuses more on eating legumes, whole grains, vegetables, fruits, nuts, and seeds with little or no animal products.

1) No additives: Plant-based diets are minimally or not processed. So, no additives may contribute to insulin resistance.

2)Fibre: Plant-based diets are rich in cellulose and hemicellulose. Both are majorly responsible for maintaining glycemic index of the meals and improving postprandial blood sugar levels.

3) Probiotics: More commonly known as food for gut-friendly bacteria. They are the type of fibre, found in fruits, vegetables and legumes are fermented by intestinal bacteria to produce short-chain fatty acids, which also improve sugar metabolism by increasing insulin sensitivity.

4) Antioxidant-rich: Plant-based diets are usually rich in various antioxidants like-

a) Polyphenols that inhibit glucose absorption and stimulate insulin secretion

b) Magnesium promotes insulin sensitivity thereby improving sugar metabolism

Also read:Diabetes Diet: Know How Many Almonds You Should Eat To Lower Blood Sugar Levels

Diabetes diet: A healthy diet can help in controlling blood sugar levelsPhoto Credit: iStock

Glycaemic index and glycaemic load of food: Plant-based diets are rich in fibre thereby improving satiety, reducing calorie density of meals. They maintain the glycaemic index of the foods and reduce glycemic load of the meals. A perfect balance can help in improving blood sugars considerably.

Also read:Diabetes: Exercise Tips To Manage Blood Sugar Levels; Benefits Of Exercising For Diabetics

Now the question is why India is known as diabetes capital when the diet followed is predominantly vegetarian? This makes it important to highlight the downside of plant-based diet:

In case you decide to rely completely on plant-based diet a lot of thought has to go in planning and balancing the diet or else you will land up in the following:

1) Plant-based diets are loaded with carbs usually: This may affect blood sugars.

2) Less of complex carbohydrates and more of simple sugars: This will greatly impact the glycemic load of meals and ultimately the blood sugar levels.

3) Proteins deficiency: If the diet is not planned properly you may miss out on essential amino acids and also land up consuming protein-deficient diet. Hence having foods in right combination can compensate for this. Example right combination of cereals and pulses might help.

Many following plant based diet suffer from protein deficiencyPhoto Credit: iStock

4) Vitamins and minerals: Calcium and iron, no doubt many vegetables are rich in minerals like iron and calcium but due to presence of phytates, oxalates and fiber the bioavailability is low.

5) Vitamin B12: Plant diets are deficient in vitamin B12. Hence it is important to include foods fortified in Vitamin B12.

Also read:5 Nuts And Seeds Loaded With Omega-3 Fatty Acids You Must Add To Your Plant-Based Diet

It is very important to analyse the pros and cons before adopting any diet. Finally, striking the right balance and ensuring no nutritional deficiencies can not only promote good health but also optimal glycemic control!

(Mrs. Sweedal Trinidade, Senior Dietetics Officer, Dietary Services, P.D. Hinduja National Hospital and MRC, Mumbai)

Disclaimer: This content including advice provides generic information only. It is in no way a substitute for qualified medical opinion. Always consult a specialist or your own doctor for more information. NDTV does not claim responsibility for this information.

Follow this link:
Diabetes: Can A Plant Based Diet Help Control Blood Sugar Levels? Nutritionist Shares The Pros And Cons Of This Diet - NDTV

Posted in Diabetes | Comments Off on Diabetes: Can A Plant Based Diet Help Control Blood Sugar Levels? Nutritionist Shares The Pros And Cons Of This Diet – NDTV

Type 2 diabetes symptoms: The sign when peeing that may signal a ‘serious’ problem – Express

Posted: August 25, 2020 at 4:54 am

The number of people with type 2 diabetes is expected to exceed the five million mark by 2030. The number of people that officially have diabetes is estimated to be one million off the actual figure. Both this discrepancy and rise can be attributed in part to the way we prioritise imminent danger.

Human evolution has hardwired us to process pain and find ways to avoid it.

This instinct is invaluable for survival but it proves to be a bug when it comes to chronic diseases, such as diabetes.

Diabetes symptoms do not usually cause pain or make you unwell so it is easy to be blindsided to its damaging effects.

The symptoms, however subtle, should not be ignored because they usually signal something serious is up.

READ MORE:Diabetes type 2 warning - the six 'less well-recognised' symptoms of high blood sugar

According to Doctor Aragona Giuseppe, GP and medical advisor at Prescription Doctor, one subtle symptom that may spell serious problems is needing to urinate more than usual, particularly at night.

According to Dr Giuseppe, the reason for increased urination is because when you have diabetes the excess glucose builds up in your blood and your kidneys are made to work overtime to filter and absorb the excess glucose, hence the need to wee more often.

This is also the reason why people become more thirsty with type 2 diabetes - another telltale sign something serious is up, she explained.

"When your kidneys cant keep up this excess glucose is excreted into your urine which takes fluids from your bodily tissues which then leaves you dehydrated, meaning you are constantly thirsty," said Dr Giuseppe.

DON'T MISSFreddie Flintoff health: 'Didn't understand what was happening to me' - signs of condition[INSIGHT]Vitamin B12 deficiency symptoms: Paraesthesia could be major warning sign what is it?[INSIGHT]How to live longer: Spice to reduce risk of cancers, prevent diabetes and boost longevity[TIPS]

Other serious warning signs include:

As Dr Giuseppe explained, the reason people with type 2 diabetes lose weight more rapidly is because the low levels of insulin prevents the body from getting glucose from the blood and into the bodys cells to use as energy, this means that the body starts burning fat and muscle for energy which means rapid weight-loss.

According to the NHS, see a GP if:

"You'll need a blood test, which you may have to go to your local health centre for if it cannot be done at your GP surgery," explains the health body.

As it points out, the earlier diabetes is diagnosed and treatment started, the better.

If you are diagnosed with type 2 diabetes, you are usually recommended to make lifestyle changes to control your blood sugar levels.

High blood sugar levels are a constant threat if you have type 2 diabetes but you can stabilise your blood sugar by making healthy dietary decisions.

There's technically nothing you cannot eat if you have type 2 diabetes, but you'll have to limit certain foods.

Generally you should avoid starchy items, such as white pasta and bread because these foods can send blood sugar levels soaring.

That's because simple carbohydrates are broken down into glucose (blood sugar) relatively quickly.

In addition, physical exercise helps lower your blood sugar level.

"You should aim for 2.5 hours of activity a week," advises the NHS.

Here is the original post:
Type 2 diabetes symptoms: The sign when peeing that may signal a 'serious' problem - Express

Posted in Diabetes | Comments Off on Type 2 diabetes symptoms: The sign when peeing that may signal a ‘serious’ problem – Express

Page 919«..1020..918919920921..930940..»